Loading...
Market
Story
Amgen to Launch Biosimilar of Regeneron's Eylea After Tuesday Court Ruling
Oct 22, 2024, 07:13 PM
Amgen has announced the launch of its biosimilar version of Regeneron's blockbuster eye care drug Eylea. This follows a ruling by the U.S. appeals court in favor of Amgen on Tuesday, which denied Regeneron's motion for a preliminary injunction to block the biosimilar. An Amgen spokesperson said this decision marks a significant development in the pharmaceutical industry, particularly in the market for eye care treatments.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Patent infringement lawsuit • 25%
Settlement agreement • 25%
Licensing agreement • 25%
No major legal action • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%